Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy

Thumbnail Image
Fernandez-Rivas, Montserrat
Vereda, Andrea
Vickery, Brian P.
Sharma, Vibha
Nilsson, Caroline
Muraro, Antonella
Hourihane, Jonathan O'B.
DunnGalvin, Audrey
du Toit, George
Blumchen, Katharina
Journal Title
Journal ISSN
Volume Title
John Wiley & Sons, Inc.
Published Version
Research Projects
Organizational Units
Journal Issue
Background: The benefit of daily administration of Peanut (Arachis hypogaea) Allergen Powder-dnfp (PTAH)-formerly AR101-has been established in clinical trials, but limited data past the first year of treatment are available. This longitudinal analysis aimed to explore the impact of continued PTAH therapeutic maintenance dosing (300 mg/day) on efficacy, safety/tolerability, and food allergy-related quality of life.Methods: We present a subset analysis of PALISADE-ARC004 participants (aged 4-17 years) who received 300 mg PTAH daily for a total of similar to 1.5 (Group A, n = 110) or similar to 2 years (Group B, n = 32). Safety assessments included monitoring the incidence of adverse events (AEs), accidental exposures to food allergens, and adrenaline use. Efficacy was assessed by double-blind, placebo-controlled food challenge (DBPCFC); skin prick testing; peanut-specific antibody assays; and Food Allergy Quality of Life Questionnaire (FAQLQ) and Food Allergy Independent Measure (FAIM) scores.Results: Continued maintenance with PTAH increased participants' ability to tolerate peanut protein: 48.1% of completers in Group A (n = 50/104) and 80.8% in Group B (n = 21/26) tolerated 2000 mg peanut protein at exit DBPCFC without dose-limiting symptoms. Immune biomarkers showed a pattern consistent with treatment-induced desensitization. Among PTAH-continuing participants, the overall and treatment-related exposure-adjusted AE rate decreased throughout the intervention period in both groups. Clinically meaningful improvements in FAQLQ and FAIM scores over time suggest a potential link between increased desensitization as determined by the DBPCFC and improved quality of life.Conclusions: These results demonstrate that daily PTAH treatment for peanut allergy beyond 1 year leads to an improved safety/tolerability profile and continued clinical and immunological response.
Desensitization , Food allergy , Oral immunotherapy , Peanut allergy , Quality of life
Fernandez-Rivas, M., Vereda, A., Vickery, B. P., Sharma, V., Nilsson, C., Muraro, A., Hourihane, J. O'B., DunnGalvin, A., du Toit, G., Blumchen, K., Beyer, K., Smith, A., Ryan, R., Adelman, D. C. and Jones, S. M. (2021) 'Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy', Allergy, 77(3), pp. 991-1003. doi: 10.1111/all.15027
Link to publisher’s version